Amylyx Pharmaceuticals Q1 Earnings Call Highlights
Amylyx Pharmaceuticals logo Key Points Avexitide Phase 3 LUCIDITY completed dosing and the company says it’s on track for a near-term top-line readout, with management and the CFO pointing to potential readout timing around Q3 2026. Expanded access program (EAP)…











